Voices

Harold J. Burstein։ Big Year for Long-Term Endocrine Therapy in Breast Cancer

Harold J. Burstein/X

Aug 15, 2025, 15:06

Harold J. Burstein։ Big Year for Long-Term Endocrine Therapy in Breast Cancer

Harold J. Burstein, Breast cancer specialist and professor at Dana-Farber Cancer Institute and Harvard Medical School, shared a post on X:

“It has been a big year for long-term follow-up of adjuvant endocrine prescription in breast cancer.

Extended therapy. Overview shows AI treatment 5 -> 10 years lowers recurrence and distant recurrence. Esp in N+ and patients given tamoxifen in years 0-5.
Also, at ASCO, we saw long term benefit (15 year follow up) for ovarian function suppression in premenopausal women, esp. those younger (< 35/40), with higher stage cancers and higher grade cancers.
No denying the side effects of these treatments, but they do work!”

Title: Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy

Journal: The Lancet

Authors: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Read the full article.

Harold J. Burstein։ Big Year for Long-Term Endocrine Therapy in Breast Cancer

More posts featuring Harold J. Burstein on OncoDaily.

AI Breast Cancer cancer Early Breast Cancer Trialists' Collaborative Group (EBCTCG) endocrine therapy Harold J. Burstein Harvard Medical School OncoDaily Oncology

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Vinay Prasad Rejoins FDA Days After Exit

New Paper Alert: Safety and Outcomes of T-DXd Retreatment After Grade 1 ILD Recovery

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech